Plain-English translation of NCT07221149 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new drug called works better when combined with chemotherapy compared to another immunotherapy drug () also combined with chemotherapy. The trial is for people with advanced stomach cancer or related cancers in the esophagus or where they meet, who have never been treated with systemic cancer therapy before. The goal is to see if this medication can help patients live longer and improve their outcomes.
Current treatments for advanced gastric and esophageal cancers help some patients, but doctors need better options. This trial is testing whether the new treatment might be more effective or safer than the standard approach for people newly diagnosed with these cancers.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either or , both combined with chemotherapy. You will attend regular clinic visits for treatment infusions and monitoring, including blood tests and imaging scans to track how your cancer responds. The study involves both a Phase 2 portion (testing safety and early effectiveness) and a Phase 3 portion (comparing outcomes between the two treatment groups) with approximately 690 participants total.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States